Intraosseous Versus Intravenous Vancomycin in Below-Knee Amputation for Ischemic Diabetic Foot

Patients with diabetic foot infection and distal ischemia scheduled for below-knee amputation were evaluated by a multidisciplinary diabetic foot council. Eligible patients were randomized in a 1:1 ratio to receive either intraosseous or intravenous vancomycin before skin incision.

In the intraosseous group, 500 mg of vancomycin diluted in 100 mL of normal saline was administered into the proximal tibial metaphysis using a sterile intraosseous vascular access system immediately before skin incision. In the intravenous group, 500 mg of vancomycin was administered intravenously at the same preincision time point. No tourniquet was used.

During surgery, a subcutaneous soft-tissue sample was obtained from the planned amputation stump region, and a simultaneous venous serum sample was collected. Vancomycin concentrations were measured in both samples. The primary pharmacokinetic outcomes were stump subcutaneous soft-tissue vancomycin concentration, serum vancomycin concentration, tissue-to-serum concentration ratio.

Secondary outcomes included postoperative trajectories of white blood cell count, C-reactive protein, procalcitonin, and interleukin-6; early postoperative pain scores; total drain output during the first 24 hours; early wound-healing outcomes assessed using ASEPSIS scores; surgical reintervention; mortality; renal safety outcomes based on serum creatinine; and systemic adverse events including vancomycin infusion reaction, allergic reaction, symptomatic deep vein thrombosis, and pulmonary embolism.

Clarification of Registry Updates

After the original prospective registration of this study, the ClinicalTrials.gov record underwent formatting and clarification updates during PRS review. These updates were made to improve clarity, grammar, readability, units of measurement, time frames, and separation of outcome-measure entries that included more than one assessment or different units of measurement. These updates were not intended to introduce new endpoints after study initiation.

Although some safety variables were described in the original study description or clarified in the registry before the definitive analysis of study results, not all of them had been entered as formal Outcome Measures in the original registration. Therefore, renal function measures, reoperation, mortality, and systemic adverse events are reported in the manuscript as postoperative observations rather than as additional prespecified endpoints.

Inclusion criteria

• Age 18 years or older
• Diagnosis of diabetes mellitus
• Diabetic foot infection with distal ischemia
• Scheduled to undergo below-knee amputation
• Absence of a feasible further revascularization option, as determined by the cardiovascular surgery and interventional radiology teams
• Adequate circulation at and proximal to the planned below-knee amputation level for stump healing
• Ability to provide written informed consent

Exclusion criteria

• Documented allergy or hypersensitivity to vancomycin or cephalosporins
• Dialysis dependence
• Systemic vancomycin use within 48 hours before surgery
• Previous Syme amputation or more proximal amputation
• Planned amputation at a level other than below the knee
• Incomplete perioperative pharmacokinetic sampling